The current consensus recommends testing all newly diagnosed patients with advanced stage non squamous lung cancer, as well as some patients with squamous cell carcinoma with clinical features associated with higher prevalence of EGFR mutations in East Asia [9]. This evidence concerns the gene EGFR and squamous cell carcinoma.